G
Glenwood D. Goss
Researcher at Ottawa Hospital Research Institute
Publications - 212
Citations - 13065
Glenwood D. Goss is an academic researcher from Ottawa Hospital Research Institute. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 48, co-authored 209 publications receiving 11464 citations. Previous affiliations of Glenwood D. Goss include University of the Witwatersrand & Harvard University.
Papers
More filters
Journal ArticleDOI
Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
Timothy Winton,Robert B. Livingston,David H. Johnson,James R. Rigas,Michael R. Johnston,Charles Butts,Yvon Cormier,Glenwood D. Goss,Richard Inculet,Eric Vallières,Willard A Fry,Drew Bethune,Joseph Ayoub,Keyue Ding,Lesley Seymour,Barbara Graham,Ming-Sound Tsao,David R. Gandara,Kenneth A. Kesler,Todd L. Demmy,Frances A. Shepherd +20 more
TL;DR: Adjuvant vinorelbine plus cisplatin has an acceptable level of toxicity and prolongs disease-free and overall survival among patients with completely resected early-stage non-small-cell lung cancer.
Journal ArticleDOI
Probability of Cancer in Pulmonary Nodules Detected on First Screening CT
Annette McWilliams,Martin C. Tammemägi,John R. Mayo,Heidi C. Roberts,Geoffrey Liu,Kam Soghrati,Kazuhiro Yasufuku,Simon Martel,Francis Laberge,Michel Gingras,S. Atkar-Khattra,Christine D. Berg,Kenneth R. Evans,Richard J. Finley,John Yee,John C. English,Paola Nasute,John R. Goffin,Serge Puksa,Lori Stewart,Scott Tsai,Michael R. Johnston,Daria Manos,Garth Nicholas,Glenwood D. Goss,Jean M. Seely,Kayvan Amjadi,Alain Tremblay,Paul Burrowes,Paul MacEachern,Rick Bhatia,Ming-Sound Tsao,Stephen Lam +32 more
TL;DR: Predictive tools based on patient and nodule characteristics can be used to accurately estimate the probability that lung nodules detected on baseline screening low-dose CT scans are malignant, according to a population-based prospective study.
Journal ArticleDOI
Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review.
TL;DR: The objective of this study was to systematically review, to summarize, and to obtain an overall estimate of the effect of anemia on survival in patients with malignant disease.
Journal ArticleDOI
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer
Marc Carrier,Karim Abou-Nassar,Ranjeeta Mallick,Vicky Tagalakis,Sudeep Shivakumar,Ariah Schattner,Philip Kuruvilla,Danny Hill,Silvana Spadafora,Katerine Marquis,Mateya Trinkaus,Anna Tomiak,Agnes Y.Y. Lee,Peter L. Gross,Alejandro Lazo-Langner,Robert El-Maraghi,Glenwood D. Goss,Grégoire Le Gal,David J. Stewart,Tim Ramsay,Marc A. Rodger,Debra Witham,Philip S. Wells,Avert Investigators +23 more
TL;DR: Apixaban therapy resulted in a significantly lower rate of venous thromboembolism than did placebo among intermediate‐to‐high‐risk ambulatory patients with cancer who were starting chemotherapy.
Journal ArticleDOI
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Glenwood D. Goss,Chun-Ming Tsai,Frances A. Shepherd,Lyudmila Bazhenova,Jong Seok Lee,Gee-Chen Chang,Lucio Crinò,Miyako Satouchi,Quincy Chu,Toyoaki Hida,Ji-Youn Han,Oscar Juan,Frank Dunphy,Makoto Nishio,Jin-Hyoung Kang,Margarita Majem,Helen Mann,Mireille Cantarini,Serban Ghiorghiu,Tetsuya Mitsudomi +19 more
TL;DR: Osimertinib showed clinical activity with manageable side-effects in patients with EGFR Thr790Met-positive non-small-cell lung cancer and could be a suitable treatment for patients who have progressed on an EGFR tyrosine-kinase inhibitor.